Atossa Genetics Inc. (NASDAQ:ATOS) Receives $20.33 Average PT from Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $20.3333.

A number of equities research analysts recently weighed in on the stock. Ascendiant Capital Markets lowered their target price on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, April 10th. Rodman & Renshaw initiated coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price target for the company. Finally, Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th.

Institutional Investors Weigh In On Atossa Genetics

A number of large investors have recently added to or reduced their stakes in the company. Graham Capital Management L.P. raised its holdings in shares of Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after buying an additional 45,923 shares in the last quarter. State Street Corp boosted its stake in Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after buying an additional 141,990 shares in the last quarter. Bank of America Corp DE grew its position in Atossa Genetics by 55.8% during the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after acquiring an additional 55,568 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Atossa Genetics by 39.9% during the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Atossa Genetics in the 2nd quarter worth approximately $381,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Stock Up 3.5%

Atossa Genetics stock opened at $2.39 on Friday. Atossa Genetics has a 52 week low of $1.70 and a 52 week high of $19.35. The business has a 50-day simple moving average of $2.74 and a 200 day simple moving average of $4.57. The stock has a market cap of $20.58 million, a price-to-earnings ratio of -0.74 and a beta of 1.29.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, research analysts anticipate that Atossa Genetics will post -4.3 earnings per share for the current year.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.